These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
358 related items for PubMed ID: 24417644
1. The influence of polymorphism on the manufacturability and in vitro dissolution of sulindac-containing hard gelatin capsules. Guadalupe Sánchez-González E, Yépez-Mulia L, Jesús Hernández-Abad V, Jung Cook H. Pharm Dev Technol; 2015 May; 20(3):306-13. PubMed ID: 24417644 [Abstract] [Full Text] [Related]
2. Modulating drug release profiles by lipid semi solid matrix formulations for BCS class II drug--an in vitro and an in vivo study. M K, Sistla R, Shastri NR. Drug Deliv; 2015 May; 22(3):418-26. PubMed ID: 24471823 [Abstract] [Full Text] [Related]
3. Investigations into the use of pregelatinised starch to develop powder-filled hard capsules. Gohil UC, Podczeck F, Turnbull N. Int J Pharm; 2004 Nov 05; 285(1-2):51-63. PubMed ID: 15488679 [Abstract] [Full Text] [Related]
4. The in vitro dissolution of theophylline from different types of hard shell capsules. Podczeck F, Jones BE. Drug Dev Ind Pharm; 2002 Oct 05; 28(9):1163-9. PubMed ID: 12455475 [Abstract] [Full Text] [Related]
5. Roller compaction, granulation and capsule product dissolution of drug formulations containing a lactose or mannitol filler, starch, and talc. Chang CK, Alvarez-Nunez FA, Rinella JV, Magnusson LE, Sueda K. AAPS PharmSciTech; 2008 Oct 05; 9(2):597-604. PubMed ID: 18459052 [Abstract] [Full Text] [Related]
6. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules. Piscitelli DA, Bigora S, Propst C, Goskonda S, Schwartz P, Lesko LJ, Augsburger L, Young D. Pharm Dev Technol; 1998 Nov 05; 3(4):443-52. PubMed ID: 9834946 [Abstract] [Full Text] [Related]
9. Effect of fill weight, capsule shell, and sinker design on the dissolution behavior of capsule formulations of a weak acid drug candidate BMS-309403. Wu Y, Zhao F, Paborji M. Pharm Dev Technol; 2003 Nov 05; 8(4):379-83. PubMed ID: 14601962 [Abstract] [Full Text] [Related]
13. Solid-state interaction of stearic acid with povidone and its effect on dissolution stability of capsules. Desai D, Kothari S, Huang M. Int J Pharm; 2008 Apr 16; 354(1-2):77-81. PubMed ID: 18194844 [Abstract] [Full Text] [Related]
16. Influence of capsule shell composition on the performance indicators of hypromellose capsule in comparison to hard gelatin capsules. Al-Tabakha MM, Arida AI, Fahelelbom KM, Sadek B, Saeed DA, Abu Jarad RA, Jawadi J. Drug Dev Ind Pharm; 2015 Apr 16; 41(10):1726-37. PubMed ID: 25586554 [Abstract] [Full Text] [Related]
17. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration. Agarwal V, Alayoubi A, Siddiqui A, Nazzal S. Drug Dev Ind Pharm; 2013 Nov 16; 39(11):1681-9. PubMed ID: 23072611 [Abstract] [Full Text] [Related]
18. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs. Pinheiro VA, Danopoulos P, Demirdjian L, Nogueira RJ, Dubois F. Int J Pharm Compd; 2013 Nov 16; 17(5):424-31. PubMed ID: 24459788 [Abstract] [Full Text] [Related]